BioVentrix, a medical device company headquartered in San Ramon, California, has raised $48.5 million in Series A funding from Andera Partners, Richmond Brothers, Inc., and Squarepoint Capital. The company aims to improve and expand the treatment options for congestive heart failure (CHF) caused by ischemic cardiomyopathy by developing less invasive, catheter-based approaches.

BioVentrix’s solution offers benefits to patients, payers, and providers. The treatment improves patients' survival and quality of life by treating the underlying cause of HF less invasively. For payers, the solution can reduce hospitalizations and avoid more expensive, highly invasive procedures such as transplants and LVAD. BioVentrix’s solution provides a unique offering for providers in the growing and expensive disease state of heart failure, enabling them to become pioneers in heart failure treatment.

The company’s technology, called the Revivent TC TransCatheter Ventricular Enhancement System, enables the reshaping of the heart after a heart attack, allowing it to pump blood more efficiently. The system uses micro-anchors to hold the damaged part of the heart together while a catheter delivers thermal energy to reshape nature.

The minimally invasive procedure can be performed in under an hour, and help avoid needing a heart transplant or left ventricular assist device (LVAD). Visit us for more information about their latest funding round: https://founderlodge.com/round/BioVentrix-raises-48500000-Series-A-2023-04-14-Jim-Dillon-MTIxOTA